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Background: With improved access to combination anti-
retroviral therapy (cART), children with HIV are growing into
adolescence and adulthood. If the children are deprived of the
knowledge regarding their disease, therewould be signiﬁcant chal-
lenges in coping with the disease. Hence this study was conducted
to assess the various elements of the disclosure of paediatric HIV
status.
Methods&Materials: Focus group discussionswere conducted
in June 2015 among the caregivers of HIV positive children visit-
ing an Anti-Retroviral Therapy (ART) centre in a Southern coastal
city of Karnataka, India. Snowballing method was adopted for
recruitment of the caregivers. The groups consisted of 8 members.
Anonymity was maintained by giving codes for the participants.
The discussions were conducted in Kannada, the ofﬁcial language
of Karnataka. The discussions were voice recorded, transcripts
prepared in English and analysed. Written informed consent was
taken from each participant and Ethical committee clearance was
obtained for the study.
Results: All the caregivers opined that the children have to be
informed about their HIV status mainly for their knowledge and
better adherence to self-care and medications. The caregivers felt
that they themselves have to tell the children at the comforts of
their homes,when the childwas around 7-10 years of age. Amajor-
ity of the participants felt that the children need to be told as a
process over time and not as a discrete one-time event. Theywould
also appreciate the help of the counsellors, especially in answering
the children’s questions. Although improved adherence was seen
in the older children, there were no beneﬁts among the younger
children. The negative aspects of disclosure commonly seen were
negative emotional reactions like sadness, worry or anger which
subsided over time. The children did not face any stigma or dis-
crimination following disclosure.
Conclusion: As there are more beneﬁts than harm from dis-
closing the HIV status to the child, disclosure it should occur as a
slowevolving process over time starting around7-9 years anddone
preferably by the caregivers, assisted by the counsellors. Develop-
ment of culturally appropriate interventions to facilitate disclosure
of HIV status to infected adolescents is key to improve retention,
adherence and other outcomes.
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Background: AIDS is a chronic, progressive syndrome, charac-
terized by intense viral replication and profound immunosuppres-
sion, resulting in the development of life threatening opportunistic
infections. HIV infection leads to deterioration of immune func-
tions.
The objective of the present study was to develop, optimize and
characterize engineered nanocarriers for controlled delivery of a
protease inhibitor. Lopinavir was the drug of choice as it is an effec-
tive antiretroviral drug having speciﬁc and prominent anti-HIV
action. In the present study, it is envisaged to develop and char-
acterize a controlled delivery system wherein the drug lopinavir
(LPV) will be entrapped in engineered nanocarrier.
Engineered nanocarriers targeted towards the prespeciﬁed tar-
get tissues by coupling with mannose delivers the drug in a
controlled manner to the site of action. Thus it results in increased
bioavailability and avoids the adverse effects associated with the
drug. Overall the approach leads to a safe, economical and effective
Anti-HIV formulation.
Methods & Materials: The uncoupled Solid Lipid Nanoparticles
(SLN)were prepared by Solvent diffusionmethod and then coupled
with mannose. Characterization studies were done by Scanning &
Transmission Electron Microscopy (SEM & TEM). X-ray diffraction
(XRD) and Differential scanning calorimetry (DSC) studies were per-
formed along with the in-vitro studies followed by in-vivo studies on
albino rats.
Results: In-vitro& in-vivo studies results showsMannose coated
SLNs (MSLN) deliver their contents to macrophage rich organs and
tissues, which are the reservoir of HIV. Low elimination and bet-
ter distribution proﬁle can be achieved by MSLNs. The dose of the
antiviral agent can be reduced due to the site-speciﬁc delivery from
this carrier.
